ACR: Filgotinib cleared phase IIb trials for rheumatoid arthritis

SAN FRANCISCO – Filgotinib monotherapy yielded a 72% week 12 ACR 20 response for patients with rheumatoid arthritis and a 79% response when combined with methotrexate, according to two phase IIb...